Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Electroconvulsive Therapy01:30

Electroconvulsive Therapy

2.6K
Electroconvulsive therapy (ECT), or shock therapy, remains a critical biomedical intervention for severe, treatment-resistant depression. While its origins can be traced back to Hippocrates' observations that malaria-induced convulsions alleviated mental illness, modern ECT has evolved significantly from its earlier, more primitive applications. First introduced in 1938 by Ugo Cerletti and his colleagues, ECT involves inducing controlled seizures using electrical currents. In its early...
2.6K
Mania and Antimanic Drugs: Overview01:24

Mania and Antimanic Drugs: Overview

800
Mania, a psychological condition characterized by elevated mood, increased energy, and reduced sleep need, is part of the bipolar disorder cycle. The exact cause of mania isn't entirely known, but it is thought to be a combination of genetic, environmental, and neurological factors. Bipolar disorder involves alternating manic and depressive episodes. Mood stabilizers like lithium, antipsychotics, and anticonvulsants help manage these episodes. Lithium carbonate is particularly effective as...
800
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein01:20

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

1.2K
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
1.2K
Psychosis: Goals of Pharmacotherapy01:26

Psychosis: Goals of Pharmacotherapy

706
Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation.
706
Antiepileptic Drugs: Glutamate Antagonists01:14

Antiepileptic Drugs: Glutamate Antagonists

1.3K
Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...
1.3K
Epilepsy and Seizures: Overview01:24

Epilepsy and Seizures: Overview

1.7K
Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
1.7K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Treatment-specific CT Radiomics Models To Predict Response To Neoadjuvant Therapy And Explore Individualized Treatment Selection In Gastric Cancer.

Academic radiology·2026
Same author

Fully quantitative CMR rest perfusion reveals myocardial perfusion abnormality in Kawasaki disease: Association with left ventricular Remodeling.

International journal of cardiology·2026
Same author

ANXA2<sup>+</sup>/TNR<sup>-</sup> glioblastoma subpopulation drives tumor progression through via Src-STAT3 axis and neutrophil remodeling.

International immunopharmacology·2026
Same author

Propofol attenuates pain hypersensitivity and neuroinflammation in chronic constriction injury rats by regulating miR-1249-3p/VEGFA axis.

The Korean journal of pain·2026
Same author

Genomic Analysis of Ocular Pseudomonas aeruginosa Isolates: Insights From a Predominantly Asian, Multi-Regional Dataset.

Investigative ophthalmology & visual science·2026
Same author

Global Epidemiological Survey and Genomic Analysis of Multiple Carbapenemases-Producing Citrobacter freundii.

Journal of global antimicrobial resistance·2026

Related Experiment Video

Updated: May 3, 2026

Generating Acute and Chronic Experimental Models of Motor Tic Expression in Rats
07:38

Generating Acute and Chronic Experimental Models of Motor Tic Expression in Rats

Published on: May 27, 2021

8.0K

Tourette disorder treated with valproic acid.

Lu Ye1, Steven Lippmann

  • 1*Methodist Medical Center of Illinois, Peoria, IL; and †Department of Psychiatry, University of Louisville School of Medicine.

Clinical Neuropharmacology
|January 18, 2014
PubMed
Summary

Valproic acid effectively treated a child with Tourette's Disorder and bipolar disorder. This medication reduced tics significantly in a patient resistant to other treatments, suggesting its potential for similar cases.

More Related Videos

Author Spotlight: Advancing Pediatric Epilepsy Surgery in Children Through Novel Biomarkers and Enhanced Localization
09:57

Author Spotlight: Advancing Pediatric Epilepsy Surgery in Children Through Novel Biomarkers and Enhanced Localization

Published on: September 20, 2024

3.5K
Protocol for Repetitive Transcranial Magnetic Stimulation with Symptom Provocation to Treat Obsessive-compulsive Disorder
11:17

Protocol for Repetitive Transcranial Magnetic Stimulation with Symptom Provocation to Treat Obsessive-compulsive Disorder

Published on: November 25, 2025

1.1K

Related Experiment Videos

Last Updated: May 3, 2026

Generating Acute and Chronic Experimental Models of Motor Tic Expression in Rats
07:38

Generating Acute and Chronic Experimental Models of Motor Tic Expression in Rats

Published on: May 27, 2021

8.0K
Author Spotlight: Advancing Pediatric Epilepsy Surgery in Children Through Novel Biomarkers and Enhanced Localization
09:57

Author Spotlight: Advancing Pediatric Epilepsy Surgery in Children Through Novel Biomarkers and Enhanced Localization

Published on: September 20, 2024

3.5K
Protocol for Repetitive Transcranial Magnetic Stimulation with Symptom Provocation to Treat Obsessive-compulsive Disorder
11:17

Protocol for Repetitive Transcranial Magnetic Stimulation with Symptom Provocation to Treat Obsessive-compulsive Disorder

Published on: November 25, 2025

1.1K

Area of Science:

  • Neuroscience
  • Child Psychiatry
  • Pharmacology

Background:

  • Tourette's Disorder (TD) is a neurological condition characterized by involuntary motor and vocal tics.
  • Co-occurring psychiatric conditions, such as bipolar disorder, are common in children with TD.
  • Treatment resistance is a significant challenge in managing pediatric Tourette's Disorder.

Observation:

  • A 10-year-old boy diagnosed with Tourette's Disorder and comorbid bipolar disorder was treated with valproic acid.
  • The patient had previously shown no improvement with multiple other pharmacological interventions for his tics.

Findings:

  • Valproic acid administration resulted in a marked reduction in the total number of motor tics.
  • Significant improvements were observed in tic frequency, intensity, complexity, and associated functional impairment.
  • The efficacy of valproic acid was demonstrated in a treatment-resistant pediatric case.

Implications:

  • Valproic acid shows promise as a therapeutic option for children with treatment-resistant Tourette's Disorder.
  • This case highlights the potential of mood stabilizers in managing complex tic disorders.
  • Further research is warranted to explore the role of valproic acid in pediatric Tourette's Syndrome management.